Thus, since higher CPK levels were associated with acute renal failure and the need for renal replacement therapy in patients [51], our findings suggest that therapeutic targeting of GSK3β with lithium treatment initially ameliorated rhabdomyolysis-induced AKI probably due to a decrease in CPK plasma levels. The gene discussed is PIK3C2A; the disease is acute kidney injury.